Advertisement

Cancer and Metastasis Reviews

, Volume 12, Issue 3–4, pp 325–343 | Cite as

Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis

  • Garth L. Nicolson
Article

Abstract

Once metastatic cells successfully seed at distant sites, their clinical detection and danger to the host are dependent on growth to form gross metastases. Metastatic tumor cells proliferate in response to local paracrine growth factors and inhibitors, and their growth also depends on production and responses to autocrine growth factors. A major organ-derived (paracrine) growth factor from lung tissue-conditioned medium has been isolated that differentially stimulates the growth of cells metastatic to brain or lung. Characterization of this mitogen demonstrated that it is a transferrin or a transferrin-like glycoprotein. Furthermore, antibodies to transferrin can remove significant growth activity from lung tissue-conditioned medium. Cells that are metastatic to brain or lung express greater numbers of transferrin receptors on their surfaces than cells that are poorly metastatic or metastatic to liver.

Growth responses of metastatic cells and organ preferences of colonization appear to change during progression to more malignant states. At early stages of metastatic progression there is a tendency for many common malignancies to metastasize and grow preferentially at particular sites, suggesting that paracrine growth mechanisms may dominate the growth signals at this stage of progression. In contrast, at later stages of metastatic progression widespread dissemination to various tissues and organs occurs, and autocrine growth mechanisms may dominate the growth responses of metastatic cells. Ultimately, the progression of malignant cells to completely autonomous (acrine) states can occur, and at this stage of metastatic progression cell growth may be completely independent of autocrine and paracrine growth factors or inhibitors.

Key words

tumor cell growth site-specific metastasis tumor progression growth factors growth inhibitors mitogens lung metastasis brain metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573, 1989Google Scholar
  2. 2.
    Hart IR: ‘Seed and soil’ revisited: mechanisms of site specific metastasis. Cancer Metastasis Rev 1: 5–16, 1982Google Scholar
  3. 3.
    Kiernan MW, Longenecker BM: Organ specific metastasis with special reference to avian systems. Cancer Metastasis Rev 2: 165–182, 1983Google Scholar
  4. 4.
    Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion, and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7: 143–188, 1988Google Scholar
  5. 5.
    Nicolson GL: Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948: 175–224, 1988Google Scholar
  6. 6.
    Nicolson GL: Molecular mechanisms of cancer metastasis: Tumor and host properties and the role of oncogenes and suppressor genes. Curr Opinion Oncol 3: 75–92, 1991Google Scholar
  7. 7.
    Auerbach R, Lu WC, Pardon E, Gumkowski F, Daminska G, Daminska M; Specificity of adhesion between murine tumor cells and capillary endothelium: Anin vitro correlate of preferential metastasisin vivo. Cancer Res 47: 1492–1497, 1987Google Scholar
  8. 8.
    Lichtner RB, Belloni PN, Nicolson GL: Differential adhesion of metastatic rat mammary carcinoma cells to organderived microvessel endothelial cells and subendothelial matrix. Exp Cell Biol 57: 146–152, 1989Google Scholar
  9. 9.
    Nicolson GL, Belloni PN, Tressler RJ, Dulski K, Inoue T, Cavanaugh PG: Adhesive, invasive and growth properties of selected metastatic variants of a murine large-cell lymphoma. Invasion Metastasis 9: 102–116, 1989Google Scholar
  10. 10.
    Varani J: Chemotaxis of metastatic tumor cells. Cancer Metastasis Rev 1: 17–28, 1982Google Scholar
  11. 11.
    Hujanen ES, Terranova VP: Migration of tumor cells to organ-derived chemoattractants. Cancer Res 45: 3517–3521, 1985Google Scholar
  12. 12.
    Liotta LA: Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 46: 1–7, 1986Google Scholar
  13. 13.
    Tryggvason K, Höyhtyä M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217, 1097Google Scholar
  14. 14.
    Frost P, Kerbel RS: Immunology of metastasis: can the immune response cope with disseminated tumor? Cancer Metastasis Rev 2: 239–256, 1983Google Scholar
  15. 15.
    Ciancolo GJ, Snyderman R: Effects of tumor growth on host defenses. Cancer Metastasis Rev 5: 15–27, 1986Google Scholar
  16. 16.
    Nicolson GL, Dulski KM: Organ specificity of metastatic tumor colonization is related to organ selective growth properties of malignant cells. Int J Cancer 38: 289–294, 1986Google Scholar
  17. 17.
    Horak E, Darling DL, Tarin D: Analysis of organ specific effects on metastatic tumor formation by studiesin vitro. J Natl Cancer Inst 76: 913–922, 1986Google Scholar
  18. 18.
    Nicolson GL: Differential growth properties of metastatic large cell lymphoma cells in target organ-conditioned media. Exp Cell Res 168: 572–577, 1987Google Scholar
  19. 19.
    Nicolson GL: Differential organ tissue adhesion, invasion, and growth properties of metastatic rat mammary adenocarcinoma cells. Breast Cancer Res Treat 12: 167–176, 1988Google Scholar
  20. 20.
    Belloni PN, Nicolson GL: Differential expression of cell surface glycoproteins on organ-derived murine vascular endothelia and endothelial cells. J Cell Physiol 136: 398–410, 1988Google Scholar
  21. 21.
    Belloni PN, Tressler RJ: Microvascular endothelial cell heterogeneity: Interactions with leukocytes and tumor cells. Cancer Metastasis Rev 8: 353–390, 1990Google Scholar
  22. 22.
    Doerr R, Zvibel I, Chiuten D, Dolimpio J, Reid LM: Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastasis. Cancer Res 49: 384–392, 1989Google Scholar
  23. 23.
    Pulford K, Souhami RL: The cytostatic activity of cultured Kupffer cells. Br J Cancer 51: 31–36, 1985Google Scholar
  24. 24.
    Li L, Nicolson GL, Fidler IJ: Directin vitro lysis of tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 51: 245–254, 1991Google Scholar
  25. 25.
    Nicolson GL: Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 204: 171–180, 1993Google Scholar
  26. 26.
    Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 44: 3448–3453, 1984Google Scholar
  27. 27.
    Messing EM: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50: 2530–2537, 1990Google Scholar
  28. 28.
    Smith K, Fennelly JA, Neal DE, Hall RR, Haris AL: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 49: 5810–5815, 1989Google Scholar
  29. 29.
    Ozawa S, Ueda M, Ando N, Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169–2173, 1989Google Scholar
  30. 30.
    Tandon AK, Clark GM, Chamness GC, Ulrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989Google Scholar
  31. 31.
    McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of cerB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991Google Scholar
  32. 32.
    Wada T, Qian X, Greene MI: Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347, 1990Google Scholar
  33. 33.
    Hung MC, Zhang X, Yen D-H, Zhang H-Z, He G-P, Zhang T-Q, Shi D-R: Aberrant expression of the c-erB-2/neu protooncogene in ovarian cancer. Cancer Lett 61: 95–103, 1992Google Scholar
  34. 34.
    Stern DF, Kamps MP: EGF-stimulated tyrosine phosphorylation of p185neu: a potential model fot receptor interactions. EMBO J 7: 995–1001, 1988Google Scholar
  35. 35.
    Yu D, Hamada J-I, Zhang H, Nicolson GL, Hung MC: Suppression ofneu oncogene-induced metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263–2270, 1992Google Scholar
  36. 36.
    Yu D, Scorsone K, Hung MC: Adenovirus type 5 E1A gene products act as transformation suppressors of theneu oncogene. Mol Cell Biol 11: 1745–1750, 1991Google Scholar
  37. 37.
    Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS: Ha-ras induction of the invasive phenotype results in upregulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 51: 4486–4491, 1991Google Scholar
  38. 38.
    Chackal-Roy RM, Niemeyer C, More M, Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84: 43–50, 1989Google Scholar
  39. 39.
    Kahan B: Experimental metastasis of mouse embryonal carcinoma cell lines to specific locations. Cancer Res 47: 6315–6323, 1987Google Scholar
  40. 40.
    Price JE, Naito S, Fidler IJ: Growth in an organ microenvironment as a selective process in metastasis. Clin Exp Metastasis 6: 91–102, 1988Google Scholar
  41. 41.
    Szanuiawska B, Majewski S, Maninski MJ, Noremberg K, Swierz M, Janik P: Stimulatory and inhibitory activities of lung-conditioned medium on the growth of normal and neoplastic cellsin vitro. J Nat Cancer Inst 75: 303–316, 1985Google Scholar
  42. 42.
    Yamori T, Iida H, Tsukagoshi S, Tsuruo T: Growth stimulating activity of lung extract on lung-colonizing colon 26 clones and its partial characterization. Clin Exp Metastasis 6: 131–139, 1988Google Scholar
  43. 43.
    Cavanaugh PG, Nicolson GL: Purification and some properties of lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49: 3928–3933, 1989Google Scholar
  44. 44.
    Cavanaugh PG, Nicolson GL: Lung-derived growth factor for lung-metastasizing tumor cells: identification as a transferrin. J Cell Biochem 47: 261–267, 1991Google Scholar
  45. 45.
    Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89: 6197–6201, 1992Google Scholar
  46. 46.
    Nicolson GL, Inoue T, Van Pelt C, Cavanaugh PG: Differential expression of a Mr ~ 90,000 cell surface transferrin receptor-related glycoprotein on mujrine B16 metastatic melanoma sublines selected for enhanced brain or ovary colonization. Cancer Res 50: 515–520, 1990Google Scholar
  47. 47.
    Nicolson GL, Cavanaugh PG, Inoue T: Differential stimulation of the growth of lung-metastasizing tumor cells by lung (paracrine) growth factors: identification of transferrin-like mitogens in lung tissue-conditioned medium. J Natl Cancer Inst Monogr 13: 153–161, 1992Google Scholar
  48. 48.
    Inoue T, Cavanaugh PG, Steck P, Brunner N, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors on rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156: 212–217, 1993Google Scholar
  49. 49.
    Mescher AL, Muniam SL: Transferrin and the growth-promoting effect of nerves. Int Rev Cytol 110: 1–26, 1988Google Scholar
  50. 50.
    Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130: 293–300, 1988Google Scholar
  51. 51.
    Imamura T, Mitsui Y: Heparan sulfate and heparin as a potentiator of a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 172: 92–100, 1987Google Scholar
  52. 52.
    Redini F, Moczar E, Poupon M-F: Effects of glycosaminoglycans and extracellular matrix components on metastatic rat rhabdomyosarcoma tumor and myoblast cell proliferation. Clin Exp Metastasis 8: 491–502, 1990Google Scholar
  53. 53.
    Deorr R, Zvibel I, Chiuten D, D'Olimpio J, Reid LM: Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastasis. Cancer Res 49: 384–392, 1989Google Scholar
  54. 54.
    Tucker RF, Shipley GD, Moses HL, Holley RW: Growth inhibitor from BCS-1 cells closely related to platelet type beta transforming growth factor. Science 226: 705–707, 1984Google Scholar
  55. 55.
    Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB: Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119–123, 1985Google Scholar
  56. 56.
    Mooradian DL, Purchio AF, Furcht LT: Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells. Cancer Res 50: 273–277, 1990Google Scholar
  57. 57.
    Fan D, Chakrabarty S, Reid C, Bell CW, Schackert H, Morikowa K, Fidler IJ: Clonal stimulation or inhibition of human colon carcinomas and human renal carcinomas mediated by transforming growth factor-beta 1. Cancer Commun 1: 117–126, 1989Google Scholar
  58. 58.
    Lu C, Vickers MF, Kerbel R: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89: 9215–9219, 1992Google Scholar
  59. 59.
    Sargent NSE, Oestreicher M, Haidvogl H, Madnick HM, Burger MM: Growth regulation of cancer metastases by their host organ. Proc Natl Acad Sci USA 85: 7251–7255, 1988Google Scholar
  60. 60.
    Hamada J, Cavanaugh PG, Lotan O, Nicolson GL: Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66: 349–354, 1992Google Scholar
  61. 61.
    Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U: Growth regulatory factors for normal, premalignant and malignant human cells. Adv Cancer Res 54: 213–234, 1989Google Scholar
  62. 62.
    Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS: Fibroblast interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 88: 6028–6032, 1991Google Scholar
  63. 63.
    Okumura Y, Hamada J, Cavanaugh PG, Nicolson GL: Preferential growth stimulation of metastatic rat mammary adenocarcinoma cells by organ-derived syngeneic fibroblastsin vitro. Invasion Metastasis 12: 275–283, 1993Google Scholar
  64. 64.
    Prichett TR, Wang JK, Jones PA: Mesenchymal-epithelial interactions between normal and transformed human bladder cells. Cancer Res 49: 2750–2754, 1989Google Scholar
  65. 65.
    Gleave M, Hsieh J-T, Gao C, von Eschenbach AC, Chun LWK: Acceleration of human prostate cancer growthin vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753–3761, 1991Google Scholar
  66. 66.
    Dabbous ML, Haney L, Nicolson GL, Eckley D, Woolley DE: Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Br J Cancer 63: 873–878, 1992Google Scholar
  67. 67.
    Aaronson SA: Growth factors and cancer. Science 254: 1146–1153, 1991Google Scholar
  68. 68.
    Cross M, Dexter TN: Growth factors in development, transformation and tumorigenesis. Cell 64: 271–280, 1991Google Scholar
  69. 69.
    Nicolson GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473–1487, 1987Google Scholar
  70. 70.
    Miner KM, Kawaguchi T, Uba GW, Nicolson GL: Clonal drift of cell surface, melanogenic and experimental metastatic properties ofin vivo-selected, brain meninges-colonizing murine B16 melanoma. Cancer Res 42: 4631–4638, 1982Google Scholar
  71. 71.
    Nicolson GL, Kawaguchi T, Kawaguchi M, Van Pelt C: Brain surface invasion and metastasis of murine malignant melanoma. J Neuro-Oncol 4: 209–218, 1986Google Scholar
  72. 72.
    Rogelj S, Weinberg RG, Fanning P, Klagsbrun M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331; 173–175, 1988Google Scholar
  73. 73.
    Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H: Metastatic but not primary melanoma cell lines growin vitro independently of exogenous growth factors. Int J Cancer 40: 687–690, 1987Google Scholar
  74. 74.
    Chadwick DE, Lagarde AE: Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL 39 lung fibroblasts. J Natl Cancer Inst 80: 318–325, 1988Google Scholar
  75. 75.
    Richmond A, Balantien E, Thomas HG, Flaggs G, Barton DE, Spiess J, Bordoni R, Franke U, Derynck R: Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J 7: 2025–2033, 1988Google Scholar
  76. 76.
    Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko K, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316: 823–825, 1985Google Scholar
  77. 77.
    Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metastasis Rev 10: 89–101, 1991Google Scholar
  78. 78.
    Kath R, Jambrosic J, Holland L, Rodeck U, Herlyn M: Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res 51: 2205–2211, 1991Google Scholar
  79. 79.
    Egan SE, Jarolim L, Rogeli S, Spearman M, Wright JA, Greenberg AH: Growth factor modulation of metastatic lung colonization. Anticancer Res 10: 1341–1346, 1990Google Scholar
  80. 80.
    Nicolson GL, Gallick GE, Spohn WH, Lembo TN, Tainsky MA: Transfection of activated c-H-ras EJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification in spontaneous metastatic and cell surface properties. Oncogene 7: 1127–1135, 1992Google Scholar
  81. 81.
    Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP, Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837–841, 1987Google Scholar
  82. 82.
    Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330–1334, 1978Google Scholar
  83. 83.
    Lippman ME, Dickson RB, Kasid A, Gelmann E, Davidson N, McManaway M, Huff K, Bronzirt D, Bates S, Swain S, Knabbi C: Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem 24: 147–154, 1986Google Scholar
  84. 84.
    Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48: 6691–6696, 1988Google Scholar
  85. 85.
    Nicolson GL: Paracrine/autocrine growth mechanisms in tumor metastasis. Oncol Res 4: 389–399, 1993Google Scholar
  86. 86.
    Matsui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athmymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007, 1984Google Scholar
  87. 87.
    Siegall CB, Kreitman RJ, FitzGerald DJ, Pastan I: Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res 51: 2831–2836, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Garth L. Nicolson
    • 1
  1. 1.Department of Tumor Biology (108)The University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations